Breaking Finance News

Cantor Fitzgerald disclosed Spark Therapeutics (NDAQ:ONCE), hiking its price target to $105.00 earlier today

Reporting a potential upside of 0.25%, Cantor Fitzgerald upped the price target of Spark Therapeutics (NDAQ:ONCE) to $105.00

On Thursday October 12, 2017, Raymond James released a statement about Spark Therapeutics (NDAQ:ONCE) upped the target price from $0.00 to $96.00 that suggested an upside of 0.11%.

Having a price of $84.14, Spark Therapeutics (NDAQ:ONCE) traded -2.29% lower on the day. With the last stock price down -1.97% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. ONCE has recorded a 50-day average of $85.92 and a two hundred day average of $85.92. Trade Volume was up over the average, with 1,935,299 shares of ONCE changing hands over the typical 429,008

Recent Performance Chart

Spark Therapeutics (NDAQ:ONCE)

Spark Therapeutics has with a one year low of $35.07 and a one year high of $91.75 and has a market capitalization of $0.

A total of 9 brokerages have released a report on Spark Therapeutics. zero brokerages rating the company a strong buy, five brokerages rating the company a buy, three brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally one brokerage rating the company a sell with a 12-month price target of $58.44.

General Company Details For Spark Therapeutics (NDAQ:ONCE)

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.